A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Abiraterone acetate (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Cougar Biotechnology; Janssen Research & Development
  • Most Recent Events

    • 11 Dec 2017 Results of post hoc analysis of COU-AA-301 and COU-AA-302 assessing relationships between changes in PRO measures and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC), were published in the Annals of Oncology.
    • 05 Jul 2017 This trial has been completed in France (End date:2017-05-01).
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top